Collegium Pharmaceutical, Inc. COLL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product revenues, net by Product | |||||
| Belbuca | $221.65M+4.9% | $211.27M+16.0% | $182.1M+44.0% | $126.46M— | |
| Jornay PM | $148.86M— | —— | $0— | —— | |
| Nucynta ER | $80.99M+6.9% | $75.77M-8.3% | $82.65M+14.1% | $72.42M+2.1% | |
| Nucynta IR | $115.31M+14.5% | $100.74M-6.9% | $108.15M-3.5% | $112.06M+9.6% | |
| Symproic and other | $14.45M-4.3% | $15.1M-8.4% | $16.5M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
